Acticor Biotech SAS (ENXTPA:ALACT) - Share price, News & Analysis

ALACT fundamental analysis
Snowflake Score
Valuation	0/6
Future Growth	0/6
Past Performance	0/6
Financial Health	3/6
Dividends	0/6

ALACT Stock Overview

Acticor Biotech SAS operates as a clinical stage biotechnology company that develops drugs for the treatment of acute phase of thrombotic diseases.

Risk Analysis

Makes less than USD$1m in revenue (€0)

Currently unprofitable and not forecast to become profitable over the next 3 years

Volatile share price over the past 3 months

Does not have a meaningful market cap (€71M)

Acticor Biotech SAS Competitors

Price History & Performance

Summary of all time highs, changes and price drops for Acticor Biotech SAS
Historical stock prices
Current Share Price	€6.72
52 Week High	€9.39
52 Week Low	€4.50
Beta	0
1 Month Change	-16.00%
3 Month Change	15.86%
1 Year Change	n/a
3 Year Change	n/a
5 Year Change	n/a
Change since IPO	-4.68%

Shareholder Returns

	ALACT	FR Biotechs	FR Market
7D	-9.2%	3.6%	-1.5%
1Y	n/a	-39.9%	-18.8%

Return vs Industry: Insufficient data to determine how ALACT performed against the French Biotechs industry.

Return vs Market: Insufficient data to determine how ALACT performed against the French Market.

Price Volatility

Is ALACT's price volatile compared to industry and market?
ALACT volatility
ALACT Average Weekly Movement	8.7%
Biotechs Industry Average Movement	8.7%
Market Average Movement	6.0%
10% most volatile stocks in FR Market	10.2%
10% least volatile stocks in FR Market	3.5%

Stable Share Price: ALACT is more volatile than 75% of French stocks over the past 3 months, typically moving +/- 9% a week.

Volatility Over Time: ALACT's weekly volatility (9%) has been stable over the past year, but is still higher than 75% of French stocks.

About the Company

Founded	Employees	CEO	Website
2013	21	Gilles Avenard	https://acticor-biotech.com

Acticor Biotech SAS operates as a clinical stage biotechnology company that develops drugs for the treatment of acute phase of thrombotic diseases. The company develops glenzocimab, a humanized monoclonal antibody fragment that targets a specific platelet glycoprotein. It is also involved in two clinical programs in Phase II/III registration for the treatment of ischemic stroke; and two other Phase II trials addressing major cardiovascular emergencies with clinical results expected in ischemic stroke and Covid-19 respiratory distress syndrome.

Acticor Biotech SAS Fundamentals Summary

How do Acticor Biotech SAS's earnings and revenue compare to its market cap?
ALACT fundamental statistics
Market Cap	€70.87m
Earnings (TTM)	-€12.61m
Revenue (TTM)	n/a

0.0x

P/S Ratio

-5.6x

P/E Ratio

Is ALACT overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report
ALACT income statement (TTM)
Revenue	€0
Cost of Revenue	€0
Gross Profit	€0
Other Expenses	€12.61m
Earnings	-€12.61m

Last Reported Earnings

Dec 31, 2021

Next Earnings Date

Sep 22, 2022

Earnings per share (EPS)	-1.20
Gross Margin	0.00%
Net Profit Margin	0.00%
Debt/Equity Ratio	24.6%

How did ALACT perform over the long term?

See historical performance and comparison

Valuation

Is Acticor Biotech SAS undervalued compared to its fair value and its price relative to the market?

Valuation Score

0/6

Valuation Score 0/6

Below Fair Value
Significantly Below Fair Value
PE vs Industry
PE vs Market
PEG Ratio
PB vs Industry

6.43x

Price to Book (PB) ratio

Share Price vs. Fair Value

Below Fair Value: Insufficient data to calculate ALACT's fair value for valuation analysis.

Significantly Below Fair Value: Insufficient data to calculate ALACT's fair value for valuation analysis.

Price To Earnings Ratio

PE vs Industry: ALACT is unprofitable, so we can't compare its PE Ratio to the European Biotechs industry average.

PE vs Market: ALACT is unprofitable, so we can't compare its PE Ratio to the French market.

Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate ALACT's PEG Ratio to determine if it is good value.

Price to Book Ratio

PB vs Industry: ALACT is overvalued based on its PB Ratio (6.4x) compared to the FR Biotechs industry average (2.6x).

Future Growth

How is Acticor Biotech SAS forecast to perform in the next 1 to 3 years based on estimates from 1 analyst?

Future Growth Score

0/6

Future Growth Score 0/6

Earnings vs Savings Rate
Earnings vs Market
High Growth Earnings
Revenue vs Market
High Growth Revenue
Future ROE

64.2%

Forecasted annual earnings growth

Earnings and Revenue Growth Forecasts

Analyst Future Growth Forecasts

Earnings vs Savings Rate: ALACT is forecast to remain unprofitable over the next 3 years.

Earnings vs Market: ALACT is forecast to remain unprofitable over the next 3 years.

High Growth Earnings: ALACT is forecast to remain unprofitable over the next 3 years.

Revenue vs Market: ALACT is forecast to have no revenue next year.

High Growth Revenue: ALACT is forecast to have no revenue next year.

Earnings per Share Growth Forecasts

Future Return on Equity

Future ROE: Insufficient data to determine if ALACT's Return on Equity is forecast to be high in 3 years time

Past Performance

How has Acticor Biotech SAS performed over the past 5 years?

Past Performance Score

0/6

Past Performance Score 0/6

Quality Earnings
Growing Profit Margin
Earnings Trend
Accelerating Growth
Earnings vs Industry
High ROE

-64.8%

Last years earnings growth

Earnings and Revenue History

Quality Earnings: ALACT is currently unprofitable.

Growing Profit Margin: ALACT is currently unprofitable.

Past Earnings Growth Analysis

Earnings Trend: Insufficient data to determine if ALACT's year-on-year earnings growth rate was positive over the past 5 years.

Accelerating Growth: Unable to compare ALACT's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: ALACT is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-6.2%).

Return on Equity

High ROE: ALACT has a negative Return on Equity (-114.43%), as it is currently unprofitable.

Financial Health

How is Acticor Biotech SAS's financial position?

Financial Health Score

3/6

Financial Health Score 3/6

Short Term Liabilities
Long Term Liabilities
Debt Level
Reducing Debt
Stable Cash Runway
Forecast Cash Runway

Financial Position Analysis

Short Term Liabilities: ALACT's short term assets (€16.9M) exceed its short term liabilities (€4.1M).

Long Term Liabilities: ALACT's short term assets (€16.9M) exceed its long term liabilities (€2.8M).

Debt to Equity History and Analysis

Debt Level: ALACT has more cash than its total debt.

Reducing Debt: Insufficient data to determine if ALACT's debt to equity ratio has reduced over the past 5 years.

Balance Sheet

Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: Insufficient data to determine if ALACT has enough cash runway based on its current free cash flow.

Forecast Cash Runway: Insufficient data to determine if ALACT has enough cash runway if its free cash flow continues to grow or shrink based on historical rates.

Dividend

What is Acticor Biotech SAS current dividend yield, its reliability and sustainability?

Dividend Score

0/6

Dividend Score 0/6

Notable Dividend
High Dividend
Stable Dividend
Growing Dividend
Earnings Coverage
Future Dividend Coverage

Dividend Yield vs Market

Notable Dividend: Unable to evaluate ALACT's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate ALACT's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.

Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if ALACT's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if ALACT's dividend payments have been increasing.

Earnings Payout to Shareholders

Earnings Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.

Cash Payout to Shareholders

Cash Flow Coverage: Unable to calculate sustainability of dividends as ALACT has not reported any payouts.

Discover strong dividend paying companies

Management

How experienced are the management team and are they aligned to shareholders interests?

1.3yrs

Average board tenure

CEO

Gilles Avenard (69 yo)

no data

Tenure

Dr. Gilles Avenard, M.D serves as Founder and Chief Executive Officer at Acticor Biotech SAS and was its Chairman until June 2021 and serves as its Director. He serves as the President and Chief Executive...

Board Members

Experienced Board: ALACT's board of directors are not considered experienced ( 1.3 years average tenure), which suggests a new board.

Ownership

Who are the major shareholders and have insiders been buying or selling?

Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.

Ownership Breakdown

Dilution of Shares: ALACT only recently listed within the past 12 months.

Data	Last Updated (UTC time)
Company Analysis	2022/05/23 00:00
End of Day Share Price	2022/05/23 00:00
Earnings	2021/12/31
Annual Earnings	2021/12/31